| (19) |
 |
|
(11) |
EP 1 517 144 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
13.07.2005 Bulletin 2005/28 |
| (43) |
Date of publication A2: |
|
23.03.2005 Bulletin 2005/12 |
| (22) |
Date of filing: 30.11.1999 |
|
|
| (84) |
Designated Contracting States: |
|
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
| (30) |
Priority: |
01.12.1998 GB 9826359
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
99963344.9 / 1135490 |
| (71) |
Applicant: GLAXO GROUP LIMITED |
|
Greenford, Middlesex UB6 0NN (GB) |
|
| (72) |
Inventors: |
|
- Delany, Natalie Samantha
Stevenage Hertfordshire SG1 2NY (GB)
- Sanseau, Philippe
Stevenage Hertfordshire SG1 2NY (GB)
- Tate, Simon Nicholas
Stevenage Hertfordshire SG1 2NY (GB)
|
| (74) |
Representative: Nash, Guy Cameron et al |
|
GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB) |
|
| |
|
| (54) |
Method of identifying an antibody binding to and modulating the activity of a human
vanilloid receptor |
(57) The invention provides novel human vanilloid receptor (hVR) proteins, in particular
hVR1 and hVR3, nucleotide sequences encoding for the novel hVR proteins, and hVR proteins
for use in a method for screening for agents useful in the treatment or prophylaxis
of disorders which are responsive to modulation of hVR activity in a human patient.
The invention also provides expression vectors comprising said nucleotide sequences,
stable cell lines comprising said expression vectors, antibodies specific for the
novel hVR proteins, methods for the identification of compounds which exhibit hVR
modulating activity, compounds identifiable and identified by such methods, and methods
of treatment or prophylaxis of disorders which are responsive to modulation of hVR
activity in a human patient.